Lanny Kirsch, MD, Adaptive Biotechnologies, Seattle, WA, talks on how the use of measurable residual disease (MRD) has evolved in the past decade in the field of multiple myeloma, highlighting the advancement of techniques to measure MRD, such as flow cytometry and serum paraprotein analysis. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.